ARTICLE | Finance
The Cystic Fibrosis Powerhouse: Vertex
Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space
September 1, 2023 4:45 PM UTC
A long, winding road got Vertex Pharmaceuticals to the position it has now occupied for the past 10 years: dominating the market for cystic fibrosis therapies and driving the biotech’s valuation into the stratosphere of megacaps.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is a Back to School 2023 case study of how a company can drive material growth by commandeering a niche corner of the market; in this case, the orphan disease of cystic fibrosis...
BCIQ Company Profiles